Ellen Cavaleri
Investor Relations Contact presso LYRA THERAPEUTICS, INC.
Profilo
Ms. Ellen Cavaleri is a Senior VP-Investor Relations & Communications at Lyra Therapeutics, Inc. Ms. Cavaleri was previously employed as an Investor Relations Contact by Kadmon Holdings, Inc. She received her undergraduate degree from Vanderbilt University and an MBA from New York University.
Posizioni attive di Ellen Cavaleri
Società | Posizione | Inizio |
---|---|---|
LYRA THERAPEUTICS, INC. | Investor Relations Contact | 01/01/2022 |
Precedenti posizioni note di Ellen Cavaleri
Società | Posizione | Fine |
---|---|---|
KADMON HOLDINGS, INC. | Investor Relations Contact | - |
Formazione di Ellen Cavaleri
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Ellen Cavaleri